Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy

BACKGROUND: Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the clinical benefit of checkpoint inhibitors. An immunosuppressive microenvironmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Guozhu, Cheng, Tan, Lin, Jie, Zhang, Lanfang, Zheng, Jieling, Liu, Ying, Xie, Guobo, Wang, Baiyao, Yuan, Yawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134794/
https://www.ncbi.nlm.nih.gov/pubmed/30208943
http://dx.doi.org/10.1186/s40425-018-0401-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134794/
https://www.ncbi.nlm.nih.gov/pubmed/30208943
http://dx.doi.org/10.1186/s40425-018-0401-3

Ejemplares similares